B. Metzler seel. Sohn & Co. Holding AG Purchases New Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 36,603 shares of the company’s stock, valued at approximately $932,000.

Other institutional investors have also bought and sold shares of the company. Bfsg LLC boosted its stake in BridgeBio Pharma by 175.6% in the second quarter. Bfsg LLC now owns 1,240 shares of the company’s stock worth $31,000 after purchasing an additional 790 shares in the last quarter. Headlands Technologies LLC acquired a new position in BridgeBio Pharma in the second quarter worth $48,000. Values First Advisors Inc. acquired a new position in BridgeBio Pharma in the third quarter worth $57,000. CWM LLC boosted its stake in BridgeBio Pharma by 132.9% in the third quarter. CWM LLC now owns 3,442 shares of the company’s stock worth $88,000 after purchasing an additional 1,964 shares in the last quarter. Finally, Amalgamated Bank boosted its stake in BridgeBio Pharma by 24.7% in the second quarter. Amalgamated Bank now owns 4,863 shares of the company’s stock worth $123,000 after purchasing an additional 962 shares in the last quarter. Institutional investors and hedge funds own 99.85% of the company’s stock.

Insider Activity at BridgeBio Pharma

In other BridgeBio Pharma news, major shareholder Genetic Disorder L.P. Kkr sold 5,800,000 shares of the stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $25.75, for a total value of $149,350,000.00. Following the completion of the sale, the insider now directly owns 25,260,971 shares in the company, valued at $650,470,003.25. This represents a 18.67 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Brian C. Stephenson sold 4,156 shares of the stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $22.41, for a total value of $93,135.96. Following the completion of the sale, the chief financial officer now owns 93,758 shares of the company’s stock, valued at $2,101,116.78. This trade represents a 4.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 5,831,545 shares of company stock worth $150,056,923. 24.66% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on BBIO shares. Piper Sandler started coverage on BridgeBio Pharma in a research note on Wednesday, September 4th. They issued an “overweight” rating and a $46.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $43.00 price objective on shares of BridgeBio Pharma in a research note on Friday, October 25th. Cantor Fitzgerald restated an “overweight” rating and set a $70.00 target price on shares of BridgeBio Pharma in a research report on Monday, September 16th. Leerink Partners dropped their target price on BridgeBio Pharma from $47.00 to $46.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. Finally, Bank of America restated a “buy” rating and set a $42.00 target price on shares of BridgeBio Pharma in a research report on Wednesday, September 11th. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $47.57.

BridgeBio Pharma Trading Up 0.8 %

NASDAQ BBIO opened at $23.42 on Friday. The stock has a 50-day simple moving average of $24.96 and a 200 day simple moving average of $26.25. The company has a market capitalization of $4.43 billion, a PE ratio of -9.72 and a beta of 1.09. BridgeBio Pharma, Inc. has a 12 month low of $21.62 and a 12 month high of $44.32.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.